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Bromodomain and extraterminal domain protein inhibitors (BETi) hold great promise as a 
novel class of cancer therapeutics. As acquired resistance typically limits durable 
responses to targeted therapies, it is important to understand mechanisms by which 
tumor cells adapt to BETi. Here, through pooled shRNA screening of colorectal cancer 
cells, we identified tripartite motif-containing protein 33 (TRIM33) as a factor promoting 
sensitivity to BETi. We demonstrate that loss of TRIM33 reprograms cancer cells to a 
more resistant state through at least two mechanisms. TRIM33 silencing attenuates 
downregulation of MYC in response to BETi. Moreover, loss of TRIM33 enhances TGFβ 
receptor expression and signaling, and blocking TGFβ receptor activity potentiates the 
anti-proliferative effect of BETi. These results describe a mechanism for BETi resistance 
and suggest that combining inhibition of TGFβ signaling with BET bromodomain 
inhibition may offer new therapeutic benefits. 
 
SIGNIFICANCE STATEMENT  
Inhibitors of BET family bromodomain proteins (BETi) have generated considerable 
excitement and are in clinical trials for treatment of several cancers. Cancers treated 
with targeted therapies eventually become resistant, yet molecular mechanisms 
underlying resistance to BETi are poorly understood. To discover novel molecular 
mechanisms mediating resistance to BETi we performed an shRNA-based loss-of-
function genetic screen. We found that loss of TRIM33, a chromatin-associated E3 
ubiquitin ligase and established tumor suppressor, confers resistance to BETi. TRIM33 
loss diminished BETi-mediated reduction in MYC expression and enhanced TGFβ 
signaling. Notably, inhibition of TGFβ signaling increased sensitivity of cells to the anti-
proliferative effects of BETi. In particular, a TGFβ receptor inhibitor potentiated growth 





Epigenetic regulation of transcription is central to control of cell fate and proliferation. 
Addition or removal of a variety of specific post-translational modifications of histones 
affect the recruitment of epigenetic “readers”, proteins that selectively bind to modified 
sites and recruit transcriptional activators or repressors. Alterations in this complex 
epigenetic code contribute to a range of diseases, including cancer (1). Consequently 
pharmacological modulation of enzymes that generate or remove epigenetic 
modifications and their readers offer new therapeutic opportunities for cancer treatment 
(2).  
The bromodomain and extraterminal domain (BET) proteins are one important class of 
epigenetic readers involved in transcriptional control (1, 3). The small family of BET 
proteins (BRD2, BRD3, BRD4 and BRDT) are characterized by tandem bromodomains, 
that bind acetylated lysine residues in histones and other proteins, and a C-terminal 
extraterminal domain responsible for interactions with chromatin regulators. BET 
proteins, in particular BRD4, have been implicated as general regulators of transcription 
through recruitment of the elongation factor P-TEFb to gene promoters and through 
interaction with the mediator complex. In addition, high-level recruitment of BRD4 to 
enhancer regions has been implicated in gene-specific transcriptional activation. 
Evidence from a variety of approaches has implicated BET proteins, in particular BRD2 
and BRD4, in a range of cancers (1, 3-5) and inhibition of BET proteins offers a novel 
strategy for the treatment of cancer (3, 6). BET inhibitors (BETi) are small molecules that 
interact with the acetylated lysine binding pocket of the BET family bromodomains (6, 7), 
interfering with BET protein binding to chromatin and consequent modulation of 
transcription. BETi were initially shown to be effective in a mouse xenograft model of 
midline carcinoma, a rare cancer driven by a chromosomal translocation producing a 
BRD4-NUT fusion protein (6). BETi have subsequently proven to be effective in multiple 
models of hematologic malignancies (5, 8-13) and solid tumors (14-17) that are not 
characterized by genetic alterations in BET proteins. One key mechanism by which BETi 
suppress growth and survival of at least some types of cancer cells is by preferentially 
repressing transcription of the proto-oncogene MYC, which is often under the control of 
BRD4 (5, 10, 12, 18). Thus, BETi may provide a new mechanism to target MYC and 
other oncogenic transcription factors, which lack obvious binding pockets for small 
molecules and are thus typically considered to be “undruggable”. 
The potential of targeting BET proteins in cancer has fueled the development of a variety 
of BETi, some of which are currently undergoing clinical trials (3). However, lessons from 
other targeted cancer therapies suggest that acquired resistance will limit long-term 
responsiveness to BETi treatment. Identification of specific molecular lesions leading to 
BETi resistance may suggest specific therapeutic strategies for re-sensitizing cells to 
BETi or for prolonging therapeutic response to BETi. Here, we have performed an 
shRNA-based genetic screen to identify factors whose loss promoted resistance of colon 
carcinoma cells to two structurally unrelated BET bromodomain inhibitors. Through this 
screen, we identified TRIM33 as a factor promoting sensitivity to BETi.  
TRIM33 (also called TIF1γ) belongs to a subfamily of tripartite motif-containing (TRIM) 
E3 ubiquitin ligases that also includes TRIM24 (TIF1) and TRIM28 (TIF1). TRIM33 
and its relatives are chromatin-associated transcriptional repressors characterized by an 
N-terminal RING domain and a C-terminal PHD (plant homeodomain)-bromodomain 
cassette that interacts with post-translationally modified histone tails. TRIM33 has been 
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characterized as a key factor controlling cell fate decisions during embryonic 
development (19, 20) and is an established tumor suppressor in pancreatic cancer, 
hepatocellular carcinoma and chronic myelomonocytic leukemia (21-23). Roles of 
TRIM33 in development and as a tumor suppressor have been attributed to its ability to 
strongly modulate transforming growth factor β (TGFβ) signaling through interactions 
with SMAD family transcription factors (24, 25). TRIM33 can also positively regulate cell 
cycle progression and survival independently of TGFβ through interactions with the 
anaphase-promoting complex (26) and lineage-specific transcription factors in 
leukocytes (19, 27, 28). Here, we find that TRIM33 silencing can inhibit BETi function by 
attenuating down-regulation of MYC and by potentiating TGFβ signaling. These results 
identify potential mechanism of clinical resistance to BETi, and suggest avenues for 




Pooled shRNA library screening identifies TRIM33 as a negative regulator of BETi 
resistance 
To identify genes whose loss confers resistance to the anti-proliferative effects of BET 
bromodomain inhibitors, we performed a pooled shRNA screen in a BETi-sensitive 
colorectal cancer cell line (RKO). Screening was carried out in the presence of one of 
two structurally unrelated inhibitors: the widely used compound JQ1 and a novel BETi 
GS-626510 (Figure 1A). GS-626510 binds with high affinity and specificity to BET family 
bromodomains (Figure 1B, Table S1), and a detailed description of its development will 
be published elsewhere. Both JQ1 and GS-626510 potently inhibited growth of RKO 
cells with IC50 values of 81 nM and 33 nM respectively (Figure 1C). As anticipated for 
BRD4 inhibition, both compounds strongly decreased MYC levels in RKO cells (Figure 
1D).  RNAseq analysis showed a strong correlation between genes up- and down-
regulated following 3 h treatment of RKO cells with 1 μM of JQ1 or 0.3 μM of GS-626510 
(Figure S1A), suggesting that growth suppression by these compounds is attributable to 
a common mechanism of action.  
We generated a custom lentiviral shRNA library containing 5634 shRNA constructs 
targeting 517 genes annotated as protein kinases and 85 non-targeting control shRNAs. 
RKO cells were infected with the pooled shRNA virus, and following puromycin selection 
for infected cells, 6 x 106 cells were removed for genomic DNA extraction to serve as a 
reference (T0) population. The remaining cells were placed into each of 5 different 
inhibitor conditions: DMSO vehicle control and low and high doses of either JQ1 or GS-
626510 (Figure 1E). Cells were allowed to proliferate and were passaged when they 
approached confluence. This treatment was maintained until cells reached passage 4 
(T4). Genomic DNA was extracted and the relative abundance of each shRNA in each 
treatment condition at T4, and in the reference T0 condition, was assessed by PCR 
amplifying the integrated shRNA followed by next generation sequencing (Figure 1E). 
This allowed calculation of the relative enrichment or depletion of each individual shRNA 
at T4 compared with T0. As the library contains multiple shRNAs targeting each gene, 
we used RIGER analysis (29) to identify and rank genes preferentially targeted by 
hairpins enriched upon drug treatment but not in the DMSO-treated control cells. These 
genes presumably encode proteins that promote susceptibility to BETi. Silencing 
expression of these genes thus causes drug resistance, resulting in cells harboring their 
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respective hairpins being enriched at the end of the screen. Strikingly, TRIM33 was the 
top ranked enriched target gene in all four BETi-treated conditions, but was not enriched 
in the absence of inhibitor (Figure 1F). Tracking individual shRNAs revealed clear 
enrichment of most shRNAs targeting TRIM33 at T4 in the presence of JQ1 or GS-
626510 (Figure 1G). By contrast, TRIM33 hairpins appear to be preferentially depleted in 
the DMSO vehicle control sample. An independent replicate of this screen, carried out to 
passage 5 (T5) produced very similar results with TRIM33 ranked in the top 3 of all four 
drug conditions (Figure S1B). Thus, data from two independent screens, each performed 
with two doses of two chemically unrelated BET bromodomain inhibitors, indicate that 
TRIM33 knockdown confers a selective growth advantage in BETi-treated RKO cells. 
Notably, TRIM24, the most closely related TRIM33 family member, was also highly 
enriched in all four inhibitor treated conditions but not in the DMSO control (Figure 1F, 
S1B), supporting the potential functional relevance of TRIM33 to modulation of BETi 
sensitivity. TRIM33 and TRIM24 were included in our shRNA library on the basis of early 
reports identifying TRIM24 and TRIM28 as protein kinases (30, 31), but the absence of a 
recognizable kinase catalytic domain and lack of subsequent verification suggests that 
these proteins are unlikely to have such activity. 
BETi resistance in shTRIM33 cells is due to the specific loss of TRIM33 protein 
To verify our screening data suggesting that TRIM33 promotes sensitivity to BETi in 
cancer cells, we established stable TRIM33 knockdown RKO cells by lentiviral 
transduction and evaluated their sensitivity to JQ1 or GS-626510. Among four individual 
shRNAs tested, we chose shTRIM33-B5 (hereafter referred to as shTRIM33 unless 
otherwise noted) to silence expression of TRIM33 as it produced the most efficient 
TRIM33 knockdown at the protein level (Figure 2A). Comparison of cell proliferation of 
shCTRL and shTRIM33 cells in 15-day cultures confirmed that knocking down TRIM33 
conferred a growth advantage in the presence of BETi (Figure 2B). Notably, consistent 
with the screening data, shTRIM33 cells cultured in the absence of inhibitor exhibit a 
growth disadvantage (Figure 2B), suggesting that the effect of TRIM33 on growth in the 
presence of BETi is not due to a basal increase in cell proliferation. We extended these 
studies to compare the potency of JQ1 and GS-626510 in shCTRL and shTRIM33 cells. 
Cells were incubated with varying concentrations of JQ1 or GS-626510 for 5 days and 
the relative cell number was determined. TRIM33 knockdown produced a rightward shift 
in the growth inhibition curves for both JQ1 and GS-626510 (Figure 2C). Multiple 
replicates revealed that the IC50 value of JQ1 and GS-626510 was increased by 
approximately 3-fold in shTRIM33 cells, suggesting the shTRIM33 cells are more 
resistant to BETi (Figure 2D). This effect is not limited to RKO cells as similar 
experiments performed in a panel of colorectal, breast and prostate cancer cell lines 
revealed that TRIM33 knockdown also decreased sensitivity to JQ1 and GS-626510 in a 
subset of the cell lines tested (Figure S2A,B). Finally, in prolonged culture TRIM33 
knockdown facilitates outgrowth of BETi-treated RKO cells (Figure 2E). Similar effects 
were observed with a different shRNA targeting TRIM33 (A12) (Figure 2A, S2C), 
suggesting that results are not due to off target effects. 
To further confirm that BETi resistance caused by TRIM33-directed shRNA is due to the 
loss of TRIM33 protein and not due to off target silencing of other genes, we generated 
rescue RKO cell lines re-expressing a knockdown-resistant TRIM33 cDNA (Figure 
2F,G). shTRIM33 cells re-expressing TRIM33 (pLenti-TRIM33), but not those infected 
with an empty vector (pLenti-EV) became more sensitive to both JQ1 and GS-626510 in 
long-term culture assays (Figure 2F, bottom panel, S2D). Furthermore, in these 
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experiments, overexpression of TRIM33 in shCTRL cells increased sensitivity to both 
compounds (Figure 2F, top panel, S2D). Together, our data support the idea that 
TRIM33 promotes sensitivity to BET bromodomain inhibition.  
TRIM33 knockdown maintains MYC expression following BETi 
Given the established role of both TRIM33 and BET proteins as transcriptional 
regulators, we hypothesized that shTRIM33-mediated BETi resistance could be due to 
deregulated gene transcription. We therefore used RNAseq to investigate changes in 
gene expression resulting from treatment with BETi and with loss of TRIM33 (Table S2). 
RNAseq was performed in shCTRL and shTRIM33 cells after 3h treatment with JQ1 (1 
μM), GS-626510 (0.3 μM) or vehicle control (DMSO). Results from two independent 
replicate experiments were analyzed by DESeq. Results consistent with RNAseq data 
were obtained by measuring mRNA levels for 15 genes by qRT-PCR (Figure S3A-B).  
In keeping with previous reports (5, 10), 3-hour BETi treatment had a broad impact on 
gene expression: among the 11,277 genes reliably detected by RNAseq, approximately 
1200 genes changed by greater than 2-fold (Figure 3A-B). Consistent with prior studies 
in other cell types (5, 10), BETi treatment of RKO cells strongly reduced levels of MYC 
(5 to 6-fold). Furthermore, gene set enrichment analysis (GSEA) of transcripts down-
regulated by both inhibitors revealed significant enrichment for genes having target 
motifs for MYC or the MYC co-activator MAZ in their promoter regions (20% of 
downregulated genes, Figure 3C). In contrast to BET bromodomain inhibition, TRIM33 
KD influenced the expression of a relatively small fraction of genes (Figure 3D). 
Following TRIM33 knockdown, 272 transcripts were up regulated by at least 2-fold, while 
only 84 were down-regulated by at least 2-fold, arguing that TRIM33 works preferentially 
as a transcriptional repressor rather than an activator (32). Notably, loss of TRIM33 had 
no effect on expression of BET genes (BRD2, BRD3 and BRD4) themselves and did not 
affect BRD4 protein levels (Table S2, Figure S3C).  
Repression of MYC is believed to be a major mechanism by which BETi suppress 
growth of some cell types (10, 12). We therefore examined a potential role for MYC in 
mediating the effect of TRIM33 knockdown. Consistent with our RNAseq data (Figure 
4A), 3 h of treatment with either JQ1 or GS-626510 strongly suppressed MYC mRNA 
levels as measured by qRT-PCR (Figure 4B). Furthermore, presumably due to the short 
(20-30 min) half-life of MYC protein (33), MYC protein levels were also strongly 
suppressed (Figure 4C). While basal levels of MYC mRNA and protein were modestly 
increased in shTRIM33 cells, we found that their downregulation by BETi was 
substantially attenuated (Figure 4B-4C). Furthermore, rescue of TRIM33 protein 
expression in shTRIM33 cells partially restored MYC sensitivity to JQ1 and GS-626510 
(Figure 4B-4C). These results suggest that TRIM33 is required for the ability of BET 
inhibitors to maximally down regulate MYC. To determine whether stabilization of MYC 
may play a role in conferring resistance to BETi, we stably over-expressed MYC in RKO 
cells. Ectopically expressed MYC was resistant to BETi-mediated down regulation 
(Figure 4D). We found that while RKO cells overexpressing MYC proliferated at the 
same rate as control cells, possibly reflecting the high basal levels of MYC expression in 
this cell line, MYC over-expressing cells had a growth advantage in long-term culture in 
the presence of JQ1 or GS-626510 (Figure 4E, F). Thus, protection of MYC levels from 
downregulation is likely to contribute to BETi resistance in shTRIM33 RKO cells. 
Consistent with a role for TRIM33 in regulation of MYC expression, chromatin 
immunoprecipitation (ChIP) revealed that TRIM33 associates with the MYC promoter in 
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BETi-treated RKO cells (Fig S4A). Notably, BRD4 ChIP showed that BRD4 associated 
with similar sites in the MYC promoter and that BRD4 was displaced following BETi 
treatment (Fig S4B). These data suggest that BETi may suppress MYC expression by 
displacing BRD4 from the MYC promoter to allow recruitment of the transcriptional 
repressor TRIM33 at that site. In the absence of TRIM33 this negative regulation would 
be lost, rendering cells less sensitive to BETi 
TRIM33 knockdown potentiates TGFβ signaling and inhibition of TGFβ pathway 
increases BETi sensitivity  
While the efficacy of BETi has been linked to down-regulation of MYC expression in 
hematopoietic cancers and a subset of solid tumors, in other tumor cells BETi-mediated 
growth suppression is independent of MYC (15, 34). Notably, in contrast to what we 
observed in RKO cells, MYC levels in another colorectal cancer cell line, SK-CO-1, were 
much less sensitive to either BETi treatment or TRIM33 knockdown (Fig S4C). 
Nonetheless, in this cell line TRIM33 knockdown conferred resistance to BETi (Fig S2A 
S2B).This observation suggests that other pathways in addition to MYC signaling can 
contribute to shTRIM33 cell resistance to BETi. Gene set enrichment analysis (GSEA) of 
the RNAseq data revealed that the two signatures most differentially regulated by BETi-
treatment in shCTRL vs. shTRIM33 RKO cells corresponded to genes targeted by TGFβ 
signaling (Figure S5A). Modulation of TGFβ target genes in the context of BET inhibition 
was of interest because TRIM33 has been implicated as a regulator of TGFβ signaling 
(25, 35). Furthermore, as TGFβ signaling can promote resistance to other targeted 
therapies (36), we investigated how the pathway was altered in shTRIM33 RKO cells. 
Canonical TGFβ signaling involves TGFβ ligand-induced formation of heterotetramers 
containing dimers of the TGFβ receptor I (TβRI) and TGFβ receptor II (TβRII) serine-
threonine kinases. Receptor clustering promotes TβRII phosphorylation of TβRI, leading 
to recruitment and phosphorylation of regulatory SMADs (SMAD2/3) by TβRI. 
Phosphorylated SMAD2/3 then binds to SMAD4 to form a complex that enters the 
nucleus to drive transcription of target genes. Stimulation of control and shTRIM33 cells 
with recombinant TGFβ1 ligand revealed that phosphorylation of SMAD2 was 
dramatically potentiated in the absence of TRIM33 (Figure 5A). Thus, under conditions 
where control cells exhibited barely detectable responses to TGFβ1, SMAD2 was 
robustly phosphorylated in shTRIM33 cells. These changes were not due to differences 
in the expression level of SMAD2, which appeared uniform in control and shTRIM33 
cells (Figure 5A). TGFβ1-induced phosphorylated SMAD2 (pSMAD2) seen in shTRIM33 
cells co-immunoprecipitated with SMAD4, suggesting that the pSMAD2 enters functional 
complexes with SMAD4 (Figure 5B). Previous reports have suggested that TRIM33 
antagonizes TGFβ signaling by negatively regulating SMAD4 through either mono-
ubiquitinating SMAD4 or competing with SMAD4 for phosphorylated SMAD2/3 (24, 25). 
However, knockdown of SMAD4 in shTRIM33 cells had no impact on the TGFβ1-
mediated induction of pSMAD2 (Figure 5C). These results suggest that loss of TRIM33 
in RKO cells potentiates TGFβ signaling upstream of SMAD4, at the level of SMAD2 
phosphorylation. 
Our RNAseq data showed that the TβRII mRNA is upregulated ~2 fold in shTRIM33 
cells (Figure 5D). Furthermore, ChIP experiments revealed that TRIM33 association with 
the TRII promoter is increased by BETi while BRD4 association is decreased (Fig S4D-
E), similar to the manner that MYC is regulated by TRIM33 and BRD4. To investigate 
whether TβRII up-regulation could underlie the potentiation of TGFβ signaling that 
accompanies loss of TRIM33, we employed two different shRNAs to knockdown TβRII 
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and assessed SMAD2 phosphorylation. Both shRNAs efficiently reduced TβRII mRNA 
levels (Figure 5E) and in shTRIM33 cells they dramatically reduced TGFβ1-induced 
pSMAD2 levels (Figure 5F). Notably, when we assessed the sensitivity of these cells to 
JQ1 or GS-626510 growth inhibition we found that loss of TβRII re-sensitized the 
shTRIM33 cells to the BET bromodomain inhibitors (Figure 5G, right panel, S5B). TβRII 
knockdown also increased sensitivity of control cells to BETi (Figure 5G, left panel, 
S5B). These data suggest that a combination of TGFβ pathway inhibitors and BET 
bromodomain inhibitors may provide a more potent inhibition of cell growth and may 
provide a means to overcome resistance to BET bromodomain inhibitors. To test this 
possibility directly we used the small molecule TβRI inhibitor LY2157299 (galunisertib) 
(37, 38). Treatment with LY2157299 at a dose that can substantially block TGFβ1-
stimulated pSMAD2 (Figure 5H) greatly increased the anti-proliferative effect of JQ1 or 
GS-626510 in shTRIM33 cells, yet alone had no effect on cell growth (Figure 5I, S5C). 
As with silencing of TβRII expression, chemical inhibition of TβRI also sensitized 
shCTRL cells to BETi. Interestingly, sensitization of shTRIM33 cells to BETi by treatment 
with LY2157299 was not accompanied by down regulation of MYC (Figure 5J). Thus, 
results with both TβRII knockdown and small molecule inhibitors of TβRI strongly 
suggest that TRIM33 promotes sensitivity to BETi at least in part through attenuation of 
TGFβ signaling.  
Finally, to determine whether enhanced TGFβ signaling is sufficient to induce resistance 
to BETi we examined the consequences of over-expressing TβRII. Robust TGFβ1-
induced SMAD2 phosphorylation was detected in TβRII-overexpressing cells but not in 
the empty vector control cells (Figure S5D). However, this was insufficient to confer 
resistance to either JQ1 or GS-626510 (Figure S5E). TβRII over-expression also failed 
to protect MYC levels from downregulation by BETi treatment, even in the presence of 
exogenously added TGFβ1 (Figure S5F). Taken together, these results suggest that 
TRIM33 knockdown confers resistance to BETi through combined independent effects 





The recent discovery of small molecule BET bromodomain inhibitors and the 
demonstration of their potent anti-proliferative activity in hematological and solid tumors 
highlights the potential of BETi as anti-cancer agents. As a recurring limitation to 
targeted anti-cancer therapies is the acquisition of drug resistance, in this study we used 
pooled shRNA screening to identify genes whose silencing protects RKO colon cancer 
cells from two chemically distinct BETi: the originally characterized BET inhibitor, JQ1 
(6), and a newly developed inhibitor GS-626510. The top hit from the screen was 
TRIM33, with its close family member TRIM24 also being identified. These data suggest 
that loss of TRIM33 confers resistance to BETi, and we confirmed this in both short and 
long-term growth assays. Mechanistically, loss of TRIM33 reduces BETi-mediated down-
regulation of MYC and sensitizes cells to TGFβ signaling. Notably, inhibition of TGFβ 
signaling re-sensitizes TRIM33 knockdown cells to BETi, suggesting that combining 
TGFβ inhibitors with BETi may have therapeutic benefit. 
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Multiple studies have pointed to the oncogenic transcription factor MYC as a target of 
BETi in both hematopoietic and solid tumor cell lines (10, 12, 13). As shown previously 
for JQ1 treatment, we found that both BETi employed in our study strongly decreased 
MYC mRNA and protein levels in RKO colorectal cancer cells, and potently inhibited cell 
growth. Previously it was shown that ectopic expression of MYC partly protected a 
multiple myeloma cell line from the growth inhibitory effects of JQ1, affirming MYC 
suppression to be a major mechanism underlying growth suppression by BETi. By 
contrast, it was reported that in lung adenocarcinoma cell lines, JQ1 suppressed growth 
by downregulating the transcription factor FOSL1 rather than MYC (15), suggesting that 
alternative mechanisms may underlie the activity of BETi in solid tumors. We observed 
that MYC overexpression in RKO cells attenuated the efficacy of BETi. In addition, 
RNAseq analysis showed no reduction in FOSL1 transcript level upon BETi treatment of 
RKO cells. These observations support a central role for MYC as a key transcriptional 
target for BET bromodomains in colorectal cancer.  
To identify genes whose loss conferred resistance to BETi, we performed a pooled 
shRNA screen with a library targeting genes annotated as protein kinases. We found 
that loss of TRIM33 conferred resistance to either JQ1 or GS-626510 treatment, 
indicating that TRIM33 is required, in at least some cell types, for cells to be fully 
sensitive to BETi. In such cells, TRIM33 appears to promote downregulation of MYC by 
BETi. Classically TRIM33, TRIM24 and TRIM28 act as potent transcriptional co-
repressors when recruited to the promoters of target genes, and consistent with this 
mechanism, we found TRIM33 to associate with the MYC promoter. Notably this 
association is enhanced by BETi, possibly due to direct competition between BRD4 and 
TRIM33 for binding at these sites. Transcriptional modulation of MYC by TRIM33 could 
involve its E3 ligase activity, for example by triggering ubiquitin-mediated degradation of 
factors co-associated with promoter or enhancer regions. We attempted to test this 
model using TRIM33 mutants with impaired E3 ligase activity. Mutant TRIM33, while 
unable to restore JQ1 sensitivity in shTRIM33 cells, was also very poorly expressed, 
making it unclear whether its ligase activity was essential (data not shown).  
While our study was underway, several other groups reported alternative mechanisms of 
BETi resistance in other cancer lines (39-43). While the details of the specific adaptive 
pathways vary across cell types, a common feature of BETi resistance appears to be 
reactivation of BRD4-dependent target genes. Most of these reported models of 
resistance involve the emergence of mechanisms to drive MYC expression in the 
presence of BETi. For example, up-regulation of the transcription factor GLI2 contributes 
to acquired BETi-resistance in pancreatic cancer cells (43) by driving MYC expression, 
and in models of acute myeloid leukemia (AML) (39, 41), increased WNT signaling 
apparently bypasses BET bromodomain-mediated transcription to maintain MYC 
expression through utilization of a cryptic enhancer region. Our data show that loss of 
TRIM33 partially protects MYC levels after BETi treatment, but we did not find that loss 
of TRIM33 affected β-catenin levels or localization in RKO cells (data not shown). 
Furthermore, as judged by RNAseq analysis, we found that TRIM33 knockdown did not 
induce GLI2 in RKO cells. Thus, while TRIM33 knockdown apparently confers BETi-
resistance at least in part by preventing MYC downregulation, the pathways involved are 
distinct from those previously characterized. In cell lines where BETi function 
independently of MYC, reported mechanisms of resistance likewise appear to involve 
maintaining expression of BRD4-target genes. For example, triple negative breast 
cancer cells can acquire BETi-resistance through BRD4 hyperphosphorylation, which 
drives expression of target genes through interactions with the mediator complex in a 
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manner independent of the acetylated lysine binding pocket of its bromodomains(42). As 
with each of these described mechanisms of resistance, sparing of critical target genes 
appears to be an important component of BETi resistance caused by loss of TRIM33.  
While multiple studies have addressed adaptive responses to BETi and mechanisms of 
acquired resistance, much less is understood about factors controlling intrinsic 
susceptibility of tumors to BETi. Mutations in PIK3CA appear to confer intrinsic 
resistance to BETi in breast cancer cell lines, yet the molecular basis for this 
phenomenon is currently unknown(40). Across a panel of cell lines tested, we found no 
correlation between the level of TRIM33 protein expression and sensitivity to BETi (data 
not shown), suggesting that TRIM33 status is not predictive of intrinsic resistance. It 
remains to be seen whether loss of TRIM33 will be a clinically important mechanism for 
acquired resistance to BETi. 
A short isoform of BRD4 was recently shown to be an inhibitor of DNA damage response 
signaling by influencing chromatin structure independently of its role as a transcriptional 
activator(44). Resistance to BETi could thus theoretically arise by reduction of DNA 
damage signaling, bypassing growth arrest, We found, however, that TRIM33 
knockdown did not alter DNA damage signaling as assessed by γH2AX staining (data 
not shown) suggesting that an alternative resistance pathway must be involved.  
Consistent with prior reports implicating TRIM33 in TGFβ signaling we find that loss of 
TRIM33 sensitizes cells to TGFβ. However, in contrast to previous studies suggesting 
that TRIM33 acts as an E3 ubiquitin ligase for SMAD4, we find loss of TRIM33 strongly 
enhances SMAD2 phosphorylation independently of SMAD4 and is associated with 
increased expression of TβRII. TRIM33 may therefore act as a direct modulator of TβRII 
gene transcription. Importantly, downregulation of TGFβ signaling, either by silencing 
TβRII expression or with a small molecule inhibitor of TβRI, sensitizes TRIM33 
knockdown cells to BETi. Notably, while overexpressing TβRII is sufficient to sensitize 
cells to TGFβ1, it does not prevent BETi-mediated suppression of MYC levels or cell 
growth. Thus while promoting TGFβ signaling cannot explain all of the effects of TRIM33 
knockdown on BETi sensitivity, inhibition of TGFβ signaling is nonetheless sufficient to 
sensitize cells to BETi.  
How increased TGFβ signaling contributes to BETi resistance is unclear, but it is 
noteworthy that in non-small cell lung cancer cell lines, knockdown of mediator complex 
component MED12 confers resistance to multiple kinase inhibitors through a 
transcription-independent mechanism that results in stabilization of TβRII (36). Likewise, 
knockdown of the transcription factor SOX10 in melanoma cell lines induces BRAF 
inhibitor resistance by induction of TβRII and TGFβ signaling, ultimately resulting in 
increased receptor tyrosine kinase expression (45). In both of these contexts, TGFβ-
induced resistance to targeted therapies is associated with enhanced signaling through 
the ERK MAP kinase pathway. Notably, in addition to up-regulated Wnt signaling, BETi-
resistance in AML was also associated with up-regulated TGFβ-dependent gene 
expression (39, 41). These observations are consistent with our finding that potentiated 
TGFβ signaling contributes to shTRIM33-mediated BETi resistance and suggests that 
TGFβ inhibitors may be valuable in combination with BETi in a range of malignancies. 
The ability of TGFβ inhibitors to potentiate the effect of BETi and to function in the 
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Cell lines, antibodies and drugs. Cell lines 293T, RKO, HCT15, HCT116, LoVo, SW620, 
SW837, SK-CO-1, SW480, SW1463, MDA-MB-231, MDA-MB-415, MDA-MB-468, ZR-
75-1, LNCap and PC-3 were obtained from ATCC and maintained as suggested.  
Antibodies were purchased from Cell Signaling Technology and Abcam: TRIM33 
(#13387), SMAD2 (#5339), pSMAD2 (#3108), SMAD4 (#9515), BRD4 (#13440), actin 
(#3700) and MYC (ab32072). Recombinant human TGFβ1 was from Cell Signaling 
Technology (#8915LC). (+)-JQ1 (11187) was purchased from Cayman Chemical and 
LY2157299 (S2230) was purchased from Selleck Chemical. GS-626510 was 
synthesized at Gilead Sciences and details will be published elsewhere. 
Stable knockdown and expression cell lines. Lentiviral expression vectors for shRNAs in 
the pLKO.1 puro vector (Sigma) were used to stably knockdown TRIM33, TβRII or 
SMAD4. For stable knockdown of two genes, the shTRIM33-B5 sequence was cloned 
into pLKO.1 blast (Addgene #26655) to silence TRIM33 expression. The shRNA target 
sequences used are in Table S3. For expression of TGFRII and TRIM33, cDNAs from 
Addgene #19147 and Addgene #15734 respectively, were cloned into pLentiCMV-
hygro(DEST) (Addgene #17454)) through Gateway cloning (Invitrogen). Seven silent 
mutations were made to TRIM33 cDNA to render resistance to shTRIM33-B5. MYC 
lentiviral expression vector is from Addgene (#46970). 
Pooled shRNA screening. Pooled shRNA screens were performed similarly as described 
(29). Details are provided in Supplemental Experimental Procedures.  
Cell lysis for immunoblotting and immunoprecipitation. For immunoblotting, cells in 6-well 
plates were quickly rinsed twice with PBS and directly lysed in 150 µL SDS lysis buffer 
(62.5 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol). The lysate was then transferred to 
1.5 mL Eppendorf tubes and heated for 10 min at 95-100 ºC with intermittent vortexing. 
After spinning to remove any undissolved material and measuring the protein 
concentration using BCA assay, 20-40 µg total lysate was fractionated by SDS-PAGE 
and transferred to nitrocellulose membrane for immunoblotting. For immunoprecipitation, 
cells were rinsed quickly with ice-cold PBS and lysed in buffer (50 mM HEPES pH7.4, 
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 25 mM NaF, 1 
mM Na3VO4, 1 mM PMSF and Roche Complete Protease Inhibitor Cocktail) on ice for 15 
min. Scraped cell lysate was centrifuged at 13,200 rpm for 10 min at 4 ºC and 1 mg of 
supernatant was incubated with 1-5 µg primary antibody overnight at 4 ºC. 25 µL of 
protein A sepharose 4B (Invitrogen) was added to the tube for another 2 h, and the 
precipitate was washed 3 times and then eluted in 60 µL of Laemmli sample buffer. 20 
µL of the elution was used for immunoblotting.  
Quantitative RT-PCR analysis. Total RNA was extracted using an RNeasy® mini kit 
(Source) with on-column DNA digestion. 1 µg of total RNA was used for cDNA synthesis 
with the iScriptTM cDNA synthesis kit (Bio-Rad) as per manufacturer’s suggestion. Real-
time PCR was performed on a Bio-Rad CFX ConnectTM Real-Time System and relative 
mRNA level was calculated in CFX Manager software using the 2^ (-ΔΔCt) method. 




Cumulative cell growth assay. RKO cells (3 x 105) transduced with the indicated virus 
were plated in a single well of a 6-well plate at day 0 in the presence or absence of 
inhibitors. Three days later cells were detached, counted, and 3 x 105 cells were 
transferred to a new well. The process was repeated until day 15. The cumulative cell 
number was then calculated from fold changes and the individual cell counts at each 
passage.  
Crystal violet cell proliferation assay. Cells (5-20 x 103) were plated in each well of a 6-
well plate with 3 mL of media with or without inhibitors and cultured for 14 days 
undisturbed. Medium was aspirated, and cells were stained with crystal violet staining 
solution (0.05% w/v crystal violet, 1% formaldehyde, 1% methanol in PBS) for 30 
minutes and washed with water several times. Stained plates were then air-dried and 
imaged with ChemiDoc® using Image Lab software (Bio-Rad). To quantify the crystal 
violet staining, 1 mL of 10% acetic acid was added to each well to solubilize the stain for 
20 min and the stain was diluted 1:4 in water and absorbance was measured at 590 nm. 
Growth inhibition assay and IC50 value determination.  Cells (1000 per well) were plated 
in 96-well plates in duplicate with 1:3 serial dilutions of BETi ranging from 0.169 nM to 10 
µM or 0.1% DMSO vehicle and cultured for 120 h. The end point relative viable cell 
number was determined using CellTiter Glo by quickly decanting the media, adding 100 
µL of 1:2 CellTiter Glo reagent diluted in PBS to the well and incubating for 10 min. The 
luminescence of each well was read with a TECAN Infinite M1000Pro plate reader. IC50 
values were calculated with Prism 6 (GraphPad) by fitting the data to the “3-parameter 
log (inhibitor) vs response” equation. At least three independent growth inhibition assays 
were performed for each pair of cell lines to derive mean IC50 values. 
RNAseq data analysis and gene set enrichment analysis. See Supplemental 
Experimental Procedures. 
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Figure 1. shRNA screening reveals TRIM33 as a regulator of BETi resistance in cancer 
cells. (A) Structures of the two different BETi used in this study, JQ1 and GS-626510. 
(B) KD values of GS-626510 for 40 bromodomains (Table S1) were determined using 
BROMOscanTM (DiscoveRx). The dendrogram Image was generated using TREEspot™ 
Software Tool and reprinted with permission from KINOMEscan DiscoveRx Corporation, 
© DISCOVERX CORPORATION 2010. (C) Dose-dependent inhibition of RKO cell 
proliferation by JQ1 and GS-626510 in a 5-day assay. Relative viable cell number was 
determined by CellTiter Glo assay. (D) GS-626510 and JQ1 both down-regulate MYC 
protein levels. RKO cells were treated with increasing concentrations of BETi for 3 h and 
MYC levels in whole cell lysates were assessed by immunoblotting. Actin was used as a 
loading control. (E) Scheme of shRNA screening procedure. Cells infected by the pooled 
shRNA library were propagated through 8 doublings in presence of either DMSO vehicle 
control or different concentrations of JQ1 or GS-626510. Genomic DNA was extracted 
from the T0 (reference) and T4 conditions for determination of proviral shRNA 
abundance. (F) Top 10 enriched target genes revealed by RIGER analysis in each 
condition. (G) Multiple individual TRIM33 shRNAs are enriched in BETi-treated, but not 
in DMSO control treated, conditions. Log2 fold change (T4/T0) of each shRNA is plotted 
from the most depleted to the most enriched. Each red line represents a single shRNA 
targeting TRIM33.  
Figure 2. Loss of TRIM33 confers resistance to BETi. (A) Top, schematic of TRIM33 
domain organization and positions of two pairs of RT-PCR primers. Middle, TRIM33 
mRNA levels determined by RT-PCR in shCTRL cell line and cell lines expressing four 
different TRIM33-targeting shRNAs. Bottom, TRIM33 protein levels in these cell lines. 
(B) shCTRL or shTRIM33 cells were seeded in a 6-well plate (3 x 105 cells per well) in 
the presence of DMSO, 100 nM JQ1 or 50 nM GS-626510 and cumulative cell numbers 
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were assessed every 3 days for up to 15 days.  (C) Growth inhibition assay. shCTRL 
and shTRIM33 cells were cultured with different concentrations of JQ1 or GS-626510 for 
120 h and relative cell numbers were determined using CellTiter Glo. (D) IC50 values 
(mean ± SEM) were calculated from 5 independently performed growth inhibition assays 
using shCTRL and shTRIM33 cells. P values are based on paired t-test. (E) 2 x 104 
shCTRL or shTRIM33 cells were plated in 6-well plates, treated with DMSO, 100 nM 
JQ1, or 50 nM GS-626510 for two weeks and then stained with crystal violet. The crystal 
violet staining was quantified at 590 nm absorbance. (F) shCTRL or shTRIM33 cells 
were transduced with either an empty vector control or TRIM33-expressing lentivirus and 
cell growth was assessed as in (E). (G) TRIM33 expression levels in cells from (F) were 
assessed by immunoblotting .  
Figure 3. RNAseq analysis of vehicle or BETi-treated shCTRL or shTRIM33 cells. 
Waterfall plots show gene expression changes induced by 3 h treatment of shCTRL 
RKO cells with 1 µM JQ1 (A) or 0.3 µM GS-626510 (B). MYC (red) is down-regulated by 
both JQ1 and GS-626510. (C) Top 10 sequence motifs enriched in promoter regions of 
genes down-regulated >2-fold by JQ1 and GS-626510 in shCTRL cells were determined 
by Gene Set Enrichment Analysis (Broad Institute). (D) Gene expression changes 
induced by shTRIM33 in RKO cells.  
Figure 4. TRIM33 modulates MYC sensitivity to BETi.  (A) Normalized RNAseq reads of 
MYC mRNA from two replicate experiments before and after JQ1 or GS626510 
treatment. (B) RT-PCR quantification of MYC mRNA in shCTRL, shTRIM33 and 
shTRIM33 rescued (shTRIM33RES) cells, either untreated or treated with BETi for 3 h. (C) 
cells treated similarly as in panel (B) were analyzed for MYC protein. (D) MYC protein 
level in control or MYC over-expressing cells before and after BETi treatment for 3 h. (E) 
Crystal violet staining of control or MYC over-expressing cells growing with DMSO, JQ1 
or GS-626510 for two weeks. (F) Cumulative cell growth of control or MYC-
overexpressing cells over 15 days.  
Figure 5. Inhibition of TGFβ signaling potentiates the anti-proliferative effects of BETi. 
(A) TGFβ1 ligand stimulated phosphorylation of SMAD2 is potentiated in shTRIM33 
cells. shCTRL or shTRIM33 RKO cells were treated with increasing doses of TGFβ1 for 
25 min (left panel) or with 2 ng/ml TGFβ1 for various times (right panel), cells were lysed 
and immunoblotted for phospho-SMAD2 (pSMAD2), total SMAD2 and TRIM33. (B) 
shCTRL or shTRIM33 cells were untreated or treated with 100 pM of TGFβ1 for 25 min 
and SMAD4 was immunoprecipitated. Co-precipitating pSMAD2 was assessed by 
immunoblotting. (C) shCTRL or shTRIM33 cells were infected with lentivirus encoding 
shCTRL or one of two hairpins targeting SMAD4 (shSMAD4-3 or shSMAD4-4). Cells 
were untreated or treated with 100 pM of TGFβ1 for 25 min SMAD4, pSMAD2 and total 
SMAD2 levels were assessed by immunoblotting. (D) TGFβ receptor II (TβRII) mRNA 
from RNAseq in shCTRL and shTRIM33 cells. (E-G) Inhibition of TGFβ pathway by 
silencing TβRII increases the magnitude of cell growth inhibition by BETi. (E) RT-PCR 
quantification of TβRII mRNA levels in shCTRL and shTRIM33 cells expressing control 
(shCTRL) or two different TβRII-targeting shRNAs (shTβRII-3 and shTβRII-4). (F) Cells 
from (E) were stimulated with 100 pM of TGFβ1 for 25 min and pSMAD2 levels 
assessed by immunoblotting. (G) shCTRL cells (left) or shTRIM33 cells (right) 
expressing control and TβRII-targeting shRNAs were cultured for 2 weeks with DMSO or 
different concentrations of BETi (as indicated) and then stained with crystal violet.  (H-J) 
The TβRI inhibitor LY2157299 potentiates BETi-mediated inhibition of cell proliferation. 
(H) shTRIM33 cells were pre-treated with increasing doses of LY2157299 and then 
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exposed to 100 pM TGFβ1 for 25 min. Immunoblotting shows dose-dependent inhibition 
of pSMAD2 by LY2157299. (I) shCTRL and two shTRIM33 KD cell lines were cultured in 
the presence of JQ1 or GS-626510, with or without LY2157299 for 2 weeks  and stained 
with crystal violet. (J) shCTRL or shTRIM33 cells were treated with 1 µM JQ1 or 0.3 µM 
GS-626510 with or without 5 µM LY2157299 overnight and MYC protein levels were 
assessed by immunoblotting. 
